Print Text Size Email 

Annual Report

Interactive 2009 Annual Report
Interactive 2008 Annual Report

Page Tools

Print Page Print Page
E-mail Page E-mail Page
RSS Feeds RSS Feeds
E-mail Alerts E-mail Alerts
IR Contacts IR Contacts
Financial Tear Sheet Financial Tear Sheet


Email Alerts

Sign up to receive e-mail alerts whenever Alnylam Pharmaceuticals posts new information to the site.

Enter your e-mail address:

Investors

Click here for Proxy Materials and Annual Meeting Information

Alnylam Pharmaceuticals, a leader in RNAi therapeutics, is a biopharmaceutical company developing novel therapeutics based on a breakthrough in biology known as RNA interference, or RNAi; a discovery that enables the creation of a broad new class of human therapeutics. Using RNAi, Alnylam has built a product platform to develop a deep pipeline of drug products to treat a More >>

ALNY (Common)
ExchangeNASDAQ (US Dollar)
Price$10.29
Change (%) - 0.18 (1.72%)
Volume212,831
Data as of 05/16/12 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Webcasts
Alnylam Pharmaceuticals at JMP Group Inc Research Conference
05/15/12 2:30 p.m.

Latest News

05/10/12
Alnylam Presents Final Results from a Phase I Clinical Trial of ALN-TTR01, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of Transthyretin-Mediated Amyloidosis (ATTR)
– Results Demonstrate Rapid, Dose-Dependent, and Durable Lowering of Both Wild-Type and Mutant TTR Protein Levels, and Show Human Proof of Concept for RNAi Therapeutics using First-Generation Lipid Nanoparticle (LNP) Delivery – – Alnylam On Track for Presenting Phase I Clinical Trial Data for ALN-TTR02, using Second-Generation LNP Delivery, in the Third Quarter of 2012 – CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 10, 2012-- ... 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Home     About Alnylam     Leadership in RNAi     Programs & Pipeline     Intellectual Property     Business Development     News and Investors     Capella
Legal       Site Map    Copyright © 2008 Alnylam Pharmaceuticals, Inc. All Rights Reserved